WP1066 Clinical Trials

Size	Price	Qty
10mg	USD 147
1g	USD 2,990

Clinical Trials

Multiple clinical trials are evaluating WP1066 for advanced central nervous system malignancies and intracranial metastases, including pediatric and adult brain tumors, medulloblastoma, recurrent malignant glioma, IDH-wildtype glioblastoma, and melanoma brain metastases. Led predominantly by academic research institutions such as Emory University, Northwestern University, and M.D. Anderson Cancer Center, these Phase 1 and Phase 2 studies range from completed early-phase safety evaluations to active combination trials with radiation therapy.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT05879250	RECRUITING	Glioblastoma, IDH-Wildtype; MGMT-Unmethylated Glioblastoma	Northwestern University	2024-05-22	PHASE2
NCT04334863	COMPLETED	Brain Tumor; Medulloblastoma; Brain Metastases	Emory University	2020-05-04	PHASE1
NCT01904123	COMPLETED	Metastatic Malignant Neoplasm in the Brain; Metastatic Melanoma; Recurrent Brain Neoplasm; Recurrent Glioblastoma; Recurrent Malignant Glioma	M.D. Anderson Cancer Center	2018-07-13	PHASE1
NCT04334863	Completed	Brain Tumor\|Medulloblastoma\|Brain Metastases	Emory University\|CURE Childhood Cancer Inc.\|Peach Bowl LegACy Fund	2020-05-04	Phase 1

(data from https://clinicaltrials.gov, updated on 2026-07-22)

Check the WP1066 product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

WP1066 selectively inhibits the phosphorylation of JAK2 and STAT3 (IC50 = 2.30 μM and 2.43 μM, respectively), blocking downstream STAT5 and ERK1/2 signaling cascades to induce G0/G1 cell cycle arrest and caspase-dependent apoptosis. By suppressing oncogenic STAT3 activation and downstream HIF transcription factors, this targeting mechanism disrupts tumor cell survival and proliferation, providing therapeutic relevance for treating central nervous system malignancies such as glioblastoma, medulloblastoma, and brain metastases.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).